Cover Image
市場調查報告書

全球藥物研發外包市場預測

Drug Discovery Outsourcing Market Forecast 2016-2026: Chemistry Services, Biology Services, Lead Optimisation, Lead Identification and Screening

出版商 Visiongain Ltd 商品編碼 260308
出版日期 內容資訊 英文 232 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球藥物研發外包市場預測 Drug Discovery Outsourcing Market Forecast 2016-2026: Chemistry Services, Biology Services, Lead Optimisation, Lead Identification and Screening
出版日期: 2016年09月20日 內容資訊: 英文 232 Pages
簡介

2016年的全球藥物研發外包市場收益規模預計達到192億美元的規模。在初期的藥物研發階段中,製藥公司和生物科技企業與CRO協作致力於開發的趨勢增強。

本報告提供全球藥物研發外包市場現況與展望調查分析,藥物研發業務外包的理由與優點,主要的CRO(受託臨床試驗機關)簡介,各業務區分、各區各國的收益預測,藥物研發外包的成長推動因素、阻礙要素分析,專家的見解,SWOT分析等彙整資料,為您概述為以下內容。

第1章 報告概要

第2章 藥物研發外包:簡介

  • 外包是什麼?
  • 藥物研發外包是什麼?
  • 藥物研發業務外包的理由
  • 開發藥劑中典型性的外包流程(含產學合作)
  • 藥物研發的外包模式增進創新
  • 開發藥劑中外包流程
  • 藥物研發的外包的課題
  • CRO受歡迎的新興市場
  • 收購的策略性聯盟
  • 最新的藥物研發業務委託契約
  • 藥物研發外包相關詞彙表

第3章 全球藥物研發外包市場

  • 藥物研發外包:全球市場概要
  • 全球藥物研發外包市場部門
  • 全球藥物研發外包市場:成果與預測(各部門)
  • 各部門的市場佔有率的變化
  • 全球化學相關服務的外包市場
    • 程序庫化合物
    • 結構要素
    • 合成樹脂
    • 市場預測
  • 全球生物學相關服務的外包市場
    • 目標的識別
    • 目標的檢驗
    • 市場預測
  • 全球先導藥物最適化的外包市場
    • 藥物研發ADMET篩檢
    • 全球先導藥物最適化市場
  • 全球先導藥物的識別、篩檢的外包市場
    • 開發藥劑中篩檢手法
    • 一次篩檢
    • 市場預測

第4章 主要國家市場

  • 藥物研發外包概要
  • 主要國家市場:成果與預測
  • 市場佔有率預測
  • 年複合成長率預測
  • 美國:市場銷售額預測
  • EU5個國家:市場銷售額預測(各地區)
  • 日本:市場銷售額預測
  • 中國:市場銷售額預測
  • 印度:市場銷售額預測
  • 巴西:市場銷售額預測
  • 俄羅斯:市場銷售額預測
  • 韓國:市場銷售額預測
  • 墨西哥:市場銷售額預測
  • 其他國:市場銷售額預測

第5章 提供藥物研發服務的主要企業

  • 藥物研發外包:分裂、擴大的市場
  • 主要臨床研究委外機構的特徵
  • 主要國家提供的服務
  • Albany Molecular Research, Inc (AMRI)
  • Aptuit
  • Charles River Laboratories
  • Covance
  • Cyprotex
  • Domainex
  • Evotec
  • GenScript
  • Pharmaceutical Product Development (PPD)
  • Quintiles
  • Selcia
  • Viva Biotech
  • WIL Research Laboratories
  • WuXi AppTec

第6章 藥物研發外包市場:定性分析

  • 市場成長的促進要素及抑制因素
  • SWOT分析
  • 優勢
  • 弱點
  • 機會
  • 威脅
  • 波特的五力分析

第7章 專家的見解

第8章 總論

  • 市場概要
  • 先導藥物最適化─最快成長部門
  • 新興市場崛起
  • 聯盟、合作持續
  • 結束

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0143

Where is the drug discovery outsourcing market heading? Visiongain's new report gives you revenue predictions for the drug discovery outsourcing market and its submarkets from 2016 to 2026, helping you stay ahead.

Visiongain's new 232-page report provides revenue forecasts to 2026 for the global drug discovery outsourcing market, four leading submarkets and 13 leading national markets. The report profiles 14 leading CROs providing drug discovery outsourcing, and includes revenue forecasts and analysis to 2026 for 6 of those companies. It also includes 3 interview transcripts with industry experts regarding the current developments and the drivers of growth in the drug discovery outsourcing market.

Besides revenue forecast to 2026, this report provides market shares, business outlooks, qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial partnerships.

See revenue forecasts for leading drug discovery outsourcing sectors

Along with prediction of overall world market value to 2026, our report shows you revenue forecasting for the four services sectors at world level:

  • Chemistry services market forecast 2016-2026
  • Biology services market forecast 2016-2026
  • Lead optimisation market forecast 2016-2026
  • Lead identification and screening market forecast 2016-2026

The analysis helps you identify market potential with individual revenue forecasts, annual growth rates and CAGRs and market shares.

Discover prospects of the leading national markets for the drug discovery outsourcing

The drug discovery outsourcing market is becoming increasingly global as companies look to lower costs by off-shoring their work to CROs based in emerging economies.

You will discover individual revenue forecasts, annual growth rates, CAGRs, and market shares to 2026, as well as written supporting analyses for each of the 13 leading national markets and the rest of the world (RoW) :

  • US
  • Japan
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • China
  • Brazil
  • Russia
  • India
  • South Korea
  • Mexico
  • Rest of the World

Demand for CROs based in emerging markets will be a major driver of growth in this market.

image1

Leading companies and potential for market growth

Our new study predicts the world market for drug discovery outsourcing will reach $19.2bn in 2016. There is the increasing trend for pharmaceutical and biotech companies to form partnerships and alliances with CROs during the early drug discovery phase.

Our research profiles leading companies, assessing their financial performance and products. You will see which organisations hold the greatest potential and what services each offer. See the profiles of 14 leading companies:

  • Albany Molecular Research (AMRI)
  • Aptuit
  • Charles River Laboratories
  • Covance
  • Cyprotex
  • Domainex
  • Evotec
  • GenScript
  • Pharmaceutical Product Development (PPD)
  • Quintiles
  • Selcia
  • Viva Biotech
  • WIL Research Laboratories
  • WuXi AppTec

Table of Contents

1. Report Overview

  • 1.1 The Drug Discovery Outsourcing Market Overview
  • 1.2 Drug Discovery Outsourcing Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports

2. An Introduction to Drug Discovery Outsourcing

  • 2.1 What is Outsourcing?
  • 2.2 What is Drug Discovery Outsourcing?
  • 2.3 Why Outsource Drug Discovery?
  • 2.4 A Common Drug Discovery Model Includes Pharmaceutical Organizations Collaborating with Academia
  • 2.5 The Outsource Model for Drug Development Increases Innovation
  • 2.6 Outsourced Processes in Drug Discovery
  • 2.7 Challenges with Drug Discovery Outsourcing
  • 2.8 Emerging Markets are a Popular Destination for CROs
  • 2.9 Strategic Partnerships to Acquisitions
  • 2.10 Recent Drug Development Outsourcing Agreements
  • 2.11 Glossary of Terms Related to Drug Discovery Outsourcing

3. Global Drug Discovery Outsourcing Market and Service Area Submarkets, 2016-2026

  • 3.1 Drug Discovery Outsourcing: Global Market Overview
  • 3.2 The Global Drug Discovery Outsourcing Market Sectors
  • 3.3 The Global Drug Discovery Outsourcing Market by Sector, 2015
  • 3.4 The Global Drug Discovery Outsourcing Market by Sector, 2015-2026
  • 3.5 The Changing Market Shares by Sector, 2015-2026
  • 3.6 The Global Chemistry Services Outsourcing Market, 2015
    • 3.6.1 Libraries
    • 3.6.2 Building Blocks
    • 3.6.3 Compound Synthesis
    • 3.6.4 The Global Chemistry Services Outsourcing Market Forecast, 2015-2026
  • 3.7 The Global Biology Services Outsourcing Market, 2015
    • 3.7.1 Target Identification
    • 3.7.2 Target Validation
    • 3.7.3 The Global Biology Services Outsourcing Market Forecast, 2015-2026
  • 3.8 The Global Lead Optimisation Market, 2015
    • 3.8.1 ADMET Screening: Prevents Late Stage Failure of Clinical Trials
    • 3.8.2 The Global Lead Optimisation Market Forecast, 2015-2026
  • 3.9 The Global Lead Identification and Screening Outsourcing Market, 2015
    • 3.9.1 Methods of Screening in Drug Discovery
    • 3.9.2 Primary Screening
    • 3.9.3 The Global Lead Identification and Screening Outsourcing Market Forecast, 2015-2026

4. The Leading National Markets in the Drug Discovery Outsourcing Market 2015-2026

  • 4.1 Drug Discovery Outsourcing Overview
  • 4.2 The Leading National Markets in the Drug Discovery Outsourcing Market, 2015
  • 4.3 The Leading National Markets in the Drug Discovery Outsourcing Market, 2015-2026
  • 4.4 The Changing Market Shares of the Leading National Markets in the Drug Discovery Outsourcing Market, 2015-2026
  • 4.5 CAGRs of the Leading National Markets in the Drug Discovery Outsourcing Market, 2015-2026
  • 4.6 The US Drug Discovery Outsourcing Market Sales Forecast, 2015-2026
  • 4.7 The EU5 Drug Discovery Outsourcing Market by Region, 2015
    • 4.7.1 The EU5 Drug Discovery Outsourcing Market Forecast, 2015-2026
    • 4.7.2 CAGRs by EU5 Region, 2015-2026
    • 4.7.3 The EU5 Changing Market Shares by Country 2015-2026
      • 4.7.3.1 The German Drug Discovery Outsourcing Market Sales Forecast, 2015-2026
      • 4.7.3.2 The UK Drug Discovery Outsourcing Market Sales Forecast, 2015-2026
      • 4.7.3.3 The French Drug Discovery Outsourcing Market Sales Forecast, 2015-2026
      • 4.7.3.4 The Italian Drug Discovery Outsourcing Market Sales Forecast, 2015-2026
      • 4.7.3.5 The Spanish Drug Discovery Outsourcing Market Sales Forecast, 2015-2026
  • 4.8 The Japanese Drug Discovery Outsourcing Market Sales Forecast, 2015-2026
  • 4.9 The Chinese Drug Discovery Outsourcing Market Sales Forecast, 2015-2026
    • 4.9.1 Challenges to China's Growth
  • 4.10 The Indian Drug Discovery Outsourcing Market Sales Forecast, 2015-2026
  • 4.11 The Brazilian Drug Discovery Outsourcing Market Sales Forecast, 2015-2026
  • 4.12 The Russian Drug Discovery Outsourcing Market Sales Forecast, 2015-2026
  • 4.13 The South Korean Drug Discovery Outsourcing Market Sales Forecast, 2015-2026
  • 4.14 The Mexican Drug Discovery Outsourcing Market Sales Forecast, 2015-2026
  • 4.15 The Rest of the World Drug Discovery Outsourcing Market Sales Forecast, 2015-2026

5. Leading Companies in the Drug Discovery Outsourcing Market

  • 5.1 Drug Discovery Outsourcing: A Fragmented and Growing Marketplace
  • 5.2 Characteristics of Leading Contract Research Organisations
    • 5.2.1 A Highly Quality Workforce
    • 5.2.2 Emphasis on Intellectual Property Protection
    • 5.2.3 Long Term Working Relationship
    • 5.2.4 Success in Project Completion
    • 5.2.5 Internal Drug Discovery Programmes
  • 5.3 Service Offerings of Leading Companies in the Drug Discovery Outsourcing Market
  • 5.4 Albany Molecular Research (AMRI)
    • 5.4.1 Historical Sales and Recent Financial Performance, 2011-2014
    • 5.4.2 AMRI's Drug Discovery Services
    • 5.4.3 Internal Portfolio of Drug Discovery and Development Programme Collaborations
    • 5.4.4 AMRI (DDS) Sales Forecast, 2015-2026
  • 5.5 Aptuit
    • 5.5.1 INDIGO: Accelerating Early Drug Candidates
    • 5.5.2 Aptuit Clinical Trial Supplies
    • 5.5.3 Strategic Partnerships, Acquisitions and Divestitures
      • 5.5.3.1 Divestiture of Aseptic Clinical Manufacturing
      • 5.5.3.2 Aptuit's Extended Partnership with GSK for VeronaCentre
      • 5.5.3.3 Partnership with Siena Biotech
      • 5.5.3.4 Partnership with Laurus Labs
  • 5.6 Charles River Laboratories
    • 5.6.1 Sales and Historical Financial Performance, 2011-2014
    • 5.6.2 Charles River Laboratories: An External Acquisition Strategy
      • 5.6.2.1 Acquisition of ChanTest
      • 5.6.2.2 Acquisition of Galapagos' CRO Services Division (BioFocus and Argenta)
      • 5.6.2.3 Acquisition of VivoPath
    • 5.6.3 Charles River Laboratories: Revenue and Financial Analysis, 2014
    • 5.6.3.1 Charles River Laboratories: Historical Financial Performance by Business Segment, 2013-2014
    • 5.6.4 Charles River Laboratories Sales Forecast, 2015-2026
  • 5.7 Covance (Acquired by Laboratory Corporation of America)
    • 5.7.1 Covance: Historical Revenue and Financial Performance, 2010-2013
    • 5.7.2 Covance: Early Stage Discovery Efforts
    • 5.7.3 Agreement with Sanofi
    • 5.7.4 Agreement with Kellogg Company
    • 5.7.5 Agreement with Bio Pontis Alliance
    • 5.7.6 Agreement with Indiana Clinical and Translational Sciences Institute (CTSI)
    • 5.7.7 Agreement with EliLilly
  • 5.8 Cyprotex
    • 5.8.1 Historical Revenue and Financial Performance, 2011-2014
    • 5.8.2 Cyprotex: Revenue by Region, 2015
    • 5.8.3 Cyprotex: Revenue Analysis and Forecast 2015-2026
  • 5.9 Domainex
    • 5.9.1 Drug Pipeline
    • 5.9.2 TBK1/ IKKεInhibitors
    • 5.9.3 Methyltransferase (KMTS) Inhibitors
  • 5.10 Evotec
    • 5.10.1 Strategic Action Plan
    • 5.10.2 Evotec: Historical Revenue and Financial Analysis, 2010-2014
    • 5.10.3 EVT Integrate and EVT Innovate
    • 5.10.4 Partnerships with Pharma for Drug Discovery
      • 5.10.4.1 Partnership with Sanofi
      • 5.10.4.2 Extended Partnership with Evotec
      • 5.10.4.3 Partnership with Johnson & Johnson
      • 5.10.4.4 Partnership with AstraZeneca
      • 5.10.4.5 Partnership with Bayer Pharmaceuticals
      • 5.10.4.6 Partnership with Boehringer Ingelheim Pharma
      • 5.10.4.7 Collaboration with CHDI
      • 5.10.4.8 Collaboration with Janssen
      • 5.10.4.9 Collaboration with MedImmune
      • 5.10.4.10 Collaboration with UCBPharma
    • 5.10.5 Evotec Sales Forecast, 2015-2026
  • 5.11 GenScript
    • 5.11.1 GenScript: Agreements and Partnerships
  • 5.12 Pharmaceutical Product Development (PPD)
    • 5.12.1 PPD: Agreements, Strategic Partnerships and Private Merger
      • 5.12.1.1 Acquisition of Acurian
      • 5.12.1.2 Partnership with Elan
      • 5.12.1.3 Partnership with GSK
  • 5.13 Quintiles
    • 5.13.1 Quintiles: Historical Revenue and Financial Performance, 2009-2014
    • 5.13.2 Development Deal With Merck
    • 5.13.3 Quintiles: Acquisition of Advion Bioanalytical Labs
    • 5.13.4 Quintiles: SheddingJobs
    • 5.13.5 Quintiles Sales Forecast, 2015-2026
  • 5.14 Selcia
    • 5.14.1 A Strong Natural Product Chemistry Track Record
    • 5.14.2 Initiative with the University of Edinburgh
    • 5.14.3 Collaboration with Cantab
  • 5.15 Viva Biotech
    • 5.15.1 GPCR Targeted Discovery Programs
    • 5.15.2 Antibody Therapeutics Discovery
  • 5.16 WIL Research Laboratories
    • 5.16.1 Focus on Preclinical Research
    • 5.16.2 Acquisition of Ricerca Biosciences LLC
    • 5.16.3 Acquisition of Midwest Bio Research
  • 5.17 WuXi Apptec
    • 5.17.1 WuXi AppTec: Service Offerings
    • 5.17.2 Acquisition of Next CODE Health
    • 5.17.3 WuXiAppTec: Historical Revenue and Financial Performance, 2010-2014
    • 5.17.4 WuXiAppTec: Laboratory Services Sales Forecast, 2015-2026

6. Quantitative Analysis of the Drug Discovery Outsourcing Market, 2016-2026

  • 6.1 Drivers and Restraints in the Drug Discovery Outsourcing Market, 2016-2026
  • 6.2 SWOT Analysis of the Drug Discovery Outsourcing Market, 2016-2026
  • 6.3 Strengths
    • 6.3.1 Cost Reduction: A Central Driver for Outsourcing
    • 6.3.2 Accelerating the Discovery of Drug Candidates
    • 6.3.3 Growth of Virtual Pharmaceutical Companies
    • 6.3.4 Reduction in R&D capacity Within Big Pharma
  • 6.4 Weaknesses
    • 6.4.1 Slowing Trajectory of Growth for R&D Spending
    • 6.4.2 Increasingly Saturated Market Requires Companies to Quickly Evolve
  • 6.5 Opportunities
    • 6.5.1 The Available Scope for the Expansion of CROs
    • 6.5.2 Targeted Therapies: Advances in Biologics and Orphan Drugs
    • 6.5.3 Increasing Development of Biologics and Biosimilars
  • 6.6 Threats
    • 6.6.1 A Competitive Market is Increasing Consolidation
    • 6.6.2 Threat of Private Public Alliances
    • 6.6.3 Intellectual Property Leaks
    • 6.6.4 Challenges of Technology Transfer
  • 6.7 Porter's Five Force Analysis of the Drug Discovery Outsourcing Market
    • 6.7.1 Threat of New Entrants: Medium
    • 6.7.2 Power of Suppliers: Medium
    • 6.7.3 Threat of Substitutes: Medium
    • 6.7.4 Power of Buyers: High
    • 6.7.5 Rivalry Among Competitors: High

7. Expert Opinions

  • 7.1 Interview with Dr. Mario Polywka, Chief Operating Officer, Evotec
    • 7.1.1 Bridging the Gap Between Academia and BigPharma
    • 7.1.2 Evotec: Specialises in Certain Disease Therapies
    • 7.1.3 Complete Drug Discovery Outsourcing: A Growing Trend
    • 7.1.4 Strategies for Drug Discovery Outsourcing Expansion
    • 7.1.5 Building Trust in Collaborations
    • 7.1.6 Evotec: Proven Track Record of Success
  • 7.2 Dr. John Davis, Director of Discovery and Dave Roberts, Business Development Director, Radiochemistry, Selcia
    • 7.2.1 Growth in the Full Spectrum of Outsourcing Services
    • 7.2.2 Natural Products: Increasing Source of Drug Discovery
    • 7.2.3 Strong Pool of Early Drug Candidates
    • 7.2.4 Overcoming Drug Discovery Challenges using Drug Discovery
    • 7.2.5 Selcia: Regional Base of Clients
    • 7.2.6 Drug Discovery and Emerging Technologies
    • 7.2.7 Med Chem Plus Projects
    • 7.2.8 Varied Customer Base
    • 7.2.9 CROs: Improving Drug Discovery Productivity Levels?
  • 7.3 Interview with Dr. Paul Overton, Executive VP, Business Development & Marketing, Aptuit
    • 7.3.1 End-to-End Drug Discovery Integration Growth
    • 7.3.2 Whole Project Externalisation
    • 7.3.3 Drug Discovery Outsourcing: One of Aptuit's Fastest Growing Services
    • 7.3.4 Aptuit INDiGO® Program
    • 7.3.5 Aptuit Implementation Drug Discovery Acquisitions
    • 7.3.6 Aptuit: Adding the Intellectual Capabilities for Drug Discovery
    • 7.3.7 Several Partners in the Drug Discovery Model

8. Conclusion

  • 8.1 Market Overview
  • 8.2 Lead Optimisation will be the Fastest Growing Sector
  • 8.3 The Drug Discovery Outsourcing Market in Emerging Market Shows Huge Gains
  • 8.4 Continued Growth in Alliances and Collaborations
  • 8.5 Concluding Remarks
  • AssociatedVisiongainReports
  • VisiongainReportSalesOrderForm
  • AppendixA
  • AboutVisiongain
  • AppendixB
  • Visiongain report evaluation form

List of Tables

  • Table 1.1 The Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 1.2 The Indian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 2.1 Indication of Functions Outsourced in the Different Stages of the Drug R&D Process, 2016
  • Table 2.2 Selected Drug Discovery Outsourcing Alliances, 2013-2016
  • Table 2.2 (Cont'd) Selected Drug Discovery Outsourcing Alliances, 2013-2016
  • Table 3.1 PhMRA's Historical Estimate for its Member's Total R&D Spending ($bn), 1980-2015
  • Table 3.2 The Global Drug Discovery Outsourcing Market: Revenue ($bn), Market Share (%) by Sector, 2015
  • Table 3.3 The Global Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Sector, 2015-2026
  • Table 3.4 The Global Drug Discovery Outsourcing Market: Revenue Share (%) by Sector, 2015 , 2020 and 2026
  • Table 3.5 The Chemistry Services Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Sector, 2015-2026
  • Table 3.6 The Biology Services Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Sector, 2015-2026
  • Table 3.7 The Lead Optimisation Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Sector, 2015-2026
  • Table 3.8 Selected Source for Lead Compounds, 2015
  • Table 3.9 The Lead Identification and Screening Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.1 The Global Drug Discovery Outsourcing Market: Revenue ($bn), Market Share (%) by Region, 2015
  • Table 4.2 The Global Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2015-2026
  • Table 4.2.1 The Global Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2015-2026
  • Table 4.3 The Global Drug Discovery Outsourcing Market: Market Share (%) by Region, 2015, 2020, 2026
  • Table 4.4 The Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2015-2020, 2020-2026, 2015-2026
  • Table 4.5 The US Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.6 The US Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 4.7 The EU5 Drug Discovery Outsourcing Market: Revenue ($bn), Market Share (%) by Region, 2015
  • Table 4.8 The EU5 Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.9 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Country, 2015-2020, 2020-2026, and 2015-2026
  • Table 4.10 The EU5 Drug Discovery Outsourcing Market: Market Shares (%) by Country, 2015, 2020, 2026
  • Table 4.11 The German Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.12 The German Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 4.13 The UK Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.14 The UK Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 4.15 The French Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.16 The French Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 4.17 The Italian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.18 The Italian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 4.19 The Spanish Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.20 The Spanish Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 4.21 The Japanese Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.22 The Japanese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 4.23 The Chinese Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.24 The Chinese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 4.25 The Indian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.26 The Indian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 4.27 The Brazilian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.28 The Brazilian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 4.29 The Russian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.30 The Russian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 4.31 The South Korean Drug Discovery Outsourcing MarketForecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.32 The South Korean Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 4.33 The Mexican Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.34 The Mexican Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 4.35 The Rest of the World Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 5.1 Albany Molecular Research (AMRI): Historical Revenue ($m), 2011-2014
  • Table 5.2 AMRI: Service Offerings and Descriptions, 2015
  • Table 5.3 AMRI: Drug Discovery and Development Programmes and Project Stage, 2015
  • Table 5.4 AMRI (DDS) Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2026
  • Table 5.5 Aptuit: Services Offered and their Descriptions, 2015
  • Table 5.6 Charles River Laboratories: Services Offered by Segment, 2016
  • Table 5.7 Charles River Laboratories: Revenue ($m), AGR (%), 2011-2014
  • Table 5.8 Charles River Laboratories: Revenue ($m) by Segment, 2011-2014
  • Table 5.9 Charles River Laboratories: Revenue ($bn) by Business Segment, 2013-2014
  • Table 5.10 Charles River Laboratories Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2026
  • Table 5.11 Covance: Historical Revenue ($bn) by Business Segment, 2010-2013
  • Table 5.12 Selected Cyprotex Partnerships, 2015
  • Table 5.13 Cyprotex: Historical Revenue ($m), (£m), AGR (%), 2011-2014
  • Table 5.14 Cyprotex: Revenue ($m), Revenue Share (%) by Region, 2015
  • Table 5.15 Cyprotex Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2026
  • Table 5.16 Cyprotex Selected Collaborations
  • Table 5.17 Evotec: Historical Revenue ($m), 2010-2014
  • Table 5.18 Evotec: Discovery Pipeline, 2016
  • Table 5.19 Evotec Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2026
  • Table 5.20 GenScript: Services Offered and Descriptions, 2015
  • Table 5.21 Quintiles: Revenue ($bn), AGR (%), 2009-2014
  • Table 5.22 Quintiles Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 5.23 Selcia: Drug Discovery Services Portfolio, 2015
  • Table 5.24 VivaBiotech: Service Offerings, 2015
  • Table 5.25 WuXiAppTec: Pharmaceutical Laboratory Services and Descriptions, 2016
  • Table 5.26 WuXiAppTec: Historical Revenue ($m), AGR (%) by Business Segment, 2010-2014
  • Table 5.27 WuXiAppTec Laboratory Services Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2026
  • Table 6.1 SWOT Analysis of the Drug Discovery Outsourcing Industry, 2016-2026
  • Table 8.1 The Global Drug Discovery Outsourcing Market Forecast:
  • Revenue ($bn), CAGR (%), 2015, 2020, 2026
  • Table 8.2 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2015, 2020, 2026
  • Table 8.3 The Drug Discovery Outsourcing Market Forecast: Revenue ($bn) by Emerging Market, 2015, 2020 and 2026

List of Figures

  • Figure 1.1 The Drug Discovery Outsourcing Market: Overview of Submarkets
  • Figure 2.1Selected Tasks being Outsourced in the Pharma Industry, 2016
  • Figure 2.2 Stages of the Drug Development Cycle
  • Figure 3.1 PhMRA's Historical Estimate for its Member's Total R&D Spending ($bn), 1980-2015
  • Figure 3.2 Attrition Rate of Compounds at the Developmental Stages
  • Figure 3.3 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2015
  • Figure 3.4 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2015
  • Figure 3.5 The Global Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 3.6 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2020
  • Figure 3.7 The Global Drug Discovery Outsourcing Market: Market Shares (%)by Sector, 2026
  • Figure 3.8 The Chemistry Services Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 3.9 The Biology Services Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 3.10 An Overview of ADMET Screening in Drug Discovery
  • Figure 3.11 The Lead Optimisation Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 3.12 Typical Steps in the Lead Screening Process
  • Figure 3.13 The Lead Identification and Screening Outsourcing Market a Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.1 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Region, 2015
  • Figure 4.2 The Global Drug Discovery Outsourcing Market: Market Share (%) by Region, 2015
  • Figure 4.3 The Global Drug Discovery Outsourcing Market: Market Share (%) by Region, 2020
  • Figure 4.4 The Global Drug Discovery Outsourcing Market: Market Share (%) by Region, 2026
  • Figure 4.5 The Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2015-2020
  • Figure 4.6 The Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2020-2026
  • Figure 4.7 The Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2015-2026
  • Figure 4.8 The US Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.9 The EU5 Drug Discovery Outsourcing Market: Market Revenue ($bn) by EU5 Country, 2015
  • Figure 4.10 The EU5 Drug Discovery Outsourcing Market: Market Share (%) by Region, 2015
  • Figure 4.11 The EU5 Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.12 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Country, 2015-2020
  • Figure 4.13 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Country, 2020-2026
  • Figure 4.14 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Country, 2015-2026
  • Figure 4.15 The EU5 Drug Discovery Outsourcing Market Forecast: Market Shares (%) by Country, 2020
  • Figure 4.16 The EU5 Drug Discovery Outsourcing Market Forecast: Market Shares (%) by Country, 2026
  • Figure 4.17 The German Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.18 The UK Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.19 The French Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.20 The Italian Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), 2015-2026
  • Figure 4.21 The Spanish Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.22 The Japanese Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.23 The Chinese Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.24 The Chinese Population Demographics: Over 65 population and Forecast (millions) , 1950, 2010, 2050
  • Figure 4.25 The Indian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.26 The Brazilian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.27 The Russian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.28 The South Korean Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.29 The Mexican Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 4.30 The Rest of the World Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 5.1 Albany Molecular Research (AMRI): Historical Revenue ($m), 2011-2014
  • Figure 5.2 AMRI (DDS) Forecast: Revenue ($m), AGR (%), 2015-2026
  • Figure 5.3 Charles River Laboratories: Revenue ($m), AGR (%), 2011-2014
  • Figure 5.4 Charles River Laboratories: Revenue Share (%) by Segment, 2014
  • Figure 5.5 Charles River Laboratories: Revenue ($bn), 2013-2014
  • Figure 5.6 Charles River Laboratories: Revenue Share (%) by Business Segment, 2014
  • Figure 5.7 Charles River Laboratories Forecast: Revenue ($m), AGR (%), 2015-2026
  • Figure 5.8 Covance: Historical Revenue ($bn), 2010-2013
  • Figure 5.9 Covance: Revenue Share (%) by Segment, 2013
  • Figure 5.10 Cyprotex: Historical Revenue ($m), AGR (%), 2011-2014
  • Figure 5.11 Cyprotex: Revenue Share(%) by Region, 2015
  • Figure 5.12 Cyprotex Forecast: Revenue ($m), AGR (%), 2015-2026
  • Figure 5.13 Domainex: Drug Pipeline by Indication, 2015
  • Figure 5.14 Evotec: Historical Revenue ($m) 2010-2014
  • Figure 5.15 Evotec Forecast: Revenue ($m), AGR (%), 2015-2026
  • Figure 5.16 Quintiles: Historical Revenue ($bn), AGR (%), 2009-2014
  • Figure 5.17 Quintiles Forecast: Revenue ($bn), AGR (%), 2015-2026
  • Figure 5.18 WuXiAppTec: Historical Revenue ($m) for Laboratory Services, 2010-2014
  • Figure 5.19 WuXiAppTec Laboratory Services Forecast: Revenue ($m), AGR (%), 2015-2026
  • Figure 6.1 The Drug Discovery Outsourcing Market: Drivers and Restraints, 2016-2026
  • Figure 6.2 Porter's Five Analysis of the Companion Diagnostics Market, 2016-2026
  • Figure 8.1 The Global Drug Discovery Outsourcing Market Forecast: Revenue ($bn), 2015, 2020, 2026
  • Figure 8.2 The Global Drug Discovery Outsourcing Market Forecast: Revenue ($bn) by Sector, 2015, 2020, 2026
  • Figure 8.3 The Drug Discovery Outsourcing Market Forecast: Revenue ($bn) by Emerging Market, 2015, 2020 and 2026

Companies Listed

  • AbbVie
  • Actavis
  • Acurian
  • Advion Bioanalytical Labs
  • Albany Molecular Research (AMRI)
  • Apredica
  • Aptuit
  • Argenta
  • Ark Therapeutics
  • Astex
  • AstraZeneca
  • Auspherix
  • Bayer
  • Behrman Capital
  • Beijing Genomics Institute
  • BioCity
  • Bio Pontis Alliance
  • BioDuro
  • BioFocus
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Cantab
  • CaprionProteomics
  • Carlyle Group
  • Catalent
  • ChanTest
  • Charles River Laboratories
  • CHDI
  • CHDI Foundation
  • CONBA
  • Covance
  • Cyprotex
  • Domainex
  • Elan
  • Eli Lilly
  • Evotec
  • Exquiron Biotech
  • Forma Therapeutics
  • Galapagos
  • Genentech
  • GenScript
  • GlaxoSmithKline
  • Great Lakes Chemical Corp
  • Harvard
  • Horizon
  • Hypha Discovery
  • IMI
  • Janssen Pharmaceutical
  • JingXin
  • Johnson & Johnson
  • Kellogg Company
  • Keucept
  • Knopp Biosciences
  • Laboratory Corporation of America
  • Laurus Labs
  • MedImmune
  • Merck
  • Midwest Bio Research
  • Milner Therapeutics Institute and Consortium
  • MIT
  • Next CODE Health
  • Parexel
  • Pharmaceutical Product Development (PPD)
  • PhRMA (Pharmaceutical Research and Manufacturers of America)
  • National Institutes of Health
  • Ono
  • Proteros Biostructures
  • Quintile
  • Roche
  • Sanofi
  • Selcia
  • Shionogi
  • Siena Biotech
  • The Babraham Institute
  • The Sanger Institute
  • UCB
  • University of Cambridge
  • University of Edinburgh
  • Viva Biotech
  • Vivo Path
  • WIL Research Laboratories
  • WuXi AppTec
  • WuXi PharmaTech
Back to Top